Fortrea (FTRE) Jefferies 2024 Global Healthcare Conference summary

Business overview and recent developments

• Approaching one-year anniversary as an independent clinical services company focused on phase I–IV research.

• Maintained an average book-to-bill ratio of 1.2 since going public, with a strong pipeline in both biotech and large pharma.

• Recently sold Endpoint and Patient Access businesses, using $275 million in proceeds to pay down debt.

• Over 50% of transition services agreements exited, on track to complete most by year-end.

• Completed an immaterial restatement of 2023 financials related to legacy issues.

Strategic initiatives and differentiation

• Underwent commercial transformation with a new Chief Commercial Officer, improving processes and market approach.

• Leveraging multiple external data sources and partnerships with tech leaders like Veeva and Advarra to enhance trial efficiency.

• Focused on simplifying site technology and supporting physician investigators to improve patient recruitment.

• Prefers strong site relationships over site ownership, emphasizing flexibility and efficiency.

• Exploring AI to analyze site interactions and improve sponsor engagement.

Operational performance and financial management

• Q1 revenue and backlog conversion were impacted by low pre-spin sales and slow project ramp-up, especially in oncology.

• Addressing operational challenges by improving project hygiene, documentation readiness, and milestone focus.

• Adjusted sales incentives to prioritize higher-margin full-service clinical work.

• Monitoring revenue composition to reduce reliance on lower-margin FSP and pass-throughs.

• Maintained proportionality across clinical pharmacology, FSP, and full-service segments.